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STATEMENT OF TRANSLATIONAL RELEVANCE 
 
ABL tyrosine kinase inhibitors (TKI) are employed for chronic myeloid 
leukemia (CML) treatment and induce durable remissions in the majority of 
patients. However, resistant disease and persistence of BCR-ABL1-
independent leukemia stem and progenitor cells remain clinical challenges. 
Furthermore, ABL-TKI are associated with the risk of severe side effects in long 
term use. Therefore, novel therapeutic strategies are warranted to target 
persisting stem cells and resistant clones alone or in combination with ABL-TKI.  
We demonstrate here the activity of an Axl inhibitor, BGB324, against 
TKI-sensitive and -resistant BCR-ABL1 positive cells, including T315I-mutated 
and ponatinib-resistant primary cells. Inhibition of Axl with BGB324 exerted 
therapeutic effects in complementary T315I-mutated and ponatinib-resistant 
preclinical mouse models. BGB324 was well-tolerated in Phase 1 clinical trials 
in healthy volunteers and AML patients (BGBC001, BGBC003 ongoing). Thus 
our findings can be rapidly translated to the clinics and BGB324 holds promise 
to improve treatment of CML patients.     
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ABSTRACT 
 
Purpose: BCR-ABL kinase inhibitors are employed successfully for chronic 
myeloid leukemia (CML) treatment. However, resistant disease and persistence 
of BCR-ABL1-independent leukemia stem and progenitor cells (LSPC) remain 
clinical challenges. The receptor tyrosine kinase Axl can mediate survival and 
therapy resistance of different cancer cells. We investigated the therapeutic 
potential of Axl inhibition in CML. 
Experimental Design: We used primary cells from CML patients and TKI-
sensitive and -resistant BCR-ABL1+ CML cell lines and a novel Ponatinib-
resistant cell line KCL-22 PonR. We analyzed the effects of genetic and 
pharmacologic Axl blockade by the small molecule Axl inhibitor BGB324 in vitro 
and in vivo. In BCR-ABL1 unmutated cells we also investigated BGB324 in 
combination with imatinib. 
Results: We demonstrate overexpression of Axl receptor tyrosine kinase in 
primary cells of CML patients compared to healthy individuals, and a further 
increase of Axl expression in BCR-ABL TKI-resistant patients. We show that Axl 
blockage decreased growth of BCR-ABL TKI-sensitive CML cells including 
CD34+ cells and exerts additive effects with imatinib via inhibition of Stat5 
activation. BGB324 also inhibits BCR-ABL TKI-resistant cells, including T315I-
mutated and ponatinib-resistant primary cells. BGB324 exerted therapeutic 
effects in BCR-ABL1 T315I-mutated and ponatinib-resistant preclinical mouse 
models. Notably, BGB324 does not inhibit BCR-ABL1 and consequently inhibits 
CML independent of BCR-ABL1 mutational status. 
Conclusion: Our data show that Axl inhibition has therapeutic potential in BCR-
ABL TKI-sensitive as well as resistant CML and support the need for clinical 
trials. 
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INTRODUCTION 
 
Chronic myeloid leukemia (CML) is characterized by the presence of the 
Philadelphia (Ph) chromosome resulting from a reciprocal translocation 
between the chromosomes 9 and 22, which is present at least in 90% of CML 
cases (1, 2). This translocation results in BCR-ABL1, an oncogenic fusion 
protein. BCR-ABL1 is a constitutively activated tyrosine kinase (TK) triggering 
several pro-survival signaling pathways in CML cells, conferring a proliferative 
advantage and resistance to apoptosis (3, 4). Therefore, BCR-ABL tyrosine 
kinase inhibitors (TKI) were developed, which became the standard-of-care in 
CML. Today, five different BCR-ABL TKI, imatinib, dasatinib, nilotinib, bosutinib 
and ponatinib are approved in different clinical scenarios leading to durable 
responses in most CML patients treated (5-8). Nevertheless, resistance to BCR-
ABL TKI represents a clinical challenge in a substantial fraction of CML 
patients. Well-described mechanisms of resistance include mutations in the 
BCR-ABL1 tyrosine kinase domain, including the gate-keeper T315I mutation 
mediating resistance to all approved agents with the exception of ponatinib. 
Furthermore, BCR-ABL1 independent mechanisms of CML stem cell 
persistence and resistance hamper treatment of CML patients (9-11). 
Furthermore, BCR-ABL TKI are associated with side effects in long-term use 
(12, 13). Despite the dramatic clinical progress upon treatment with these drugs 
and the possibility to discontinue treatment in approximately 50% of patients 
(14), allogeneic stem cell transplantation represents the only proven long-term 
curative treatment (15-17). Therefore, novel therapeutic strategies are 
warranted to target persisting stem cells and resistant clones alone or in 
combination with BCR-ABL TKI.  
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An increased activation of several tyrosine kinases in imatinib- and nilotinib-
resistant cell lines and CML patients treated with these drugs were reported (18, 
19). Therefore, targeting additional kinases besides BCR-ABL1 could be a 
pertinent option to treat BCR-ABL TKI-refractory patients. Axl, a receptor 
tyrosine kinase of the Tyro3, Axl, Mer (TAM) family, is implicated in 
oncogenesis and exhibits transforming potential in CML (20). Growth arrest 
specific gene 6 (Gas6) is the only identified activating ligand for Axl (21, 22). It 
is known that Axl phosphorylation mediates intracellular signaling through 
PI3K/Akt, Erk and PLC pathways, affecting diverse cellular functions including 
enhanced cell survival and proliferation (reviewed in (23, 24)). Overexpression, 
but not mutation, of Axl contributes to drug resistance in other cancers including 
gastrointestinal stromal tumor (GIST) (25), non-small cell lung carcinoma 
(NSCLC) (26) and acute myeloid leukemia (AML) (27). The clinically applicable 
small molecule BGB324 represents a selective and potent Axl inhibitor (28). A 
Phase 1 trial of BGB324 in healthy volunteers indicated that the drug is well-
tolerated (29). Furthermore, safety, pharmacokinetics and clinical activity of 
BGB324 are currently being investigated in a Phase 1b trial in AML and lung 
cancer patients (BGBC003, BGBC004; NCT02488408, NCT02424617). Recent 
data show that BGB324 is well-tolerated and exerts anti-leukemic activity in 
AML patients. Pharmacodynamic analyses indicate that BGB324 inhibits Axl 
phosphorylation in AML patients (28). 
Thus far, Axl expression has only been investigated in less than 10 CML 
patients, yielding the result that BCR-ABL TKI-resistant unmutated BCR-ABL1 
CML cells express higher levels of Axl compared to BCR-ABL TKI-sensitive 
cells (30, 31). Expression of Axl in BCR-ABL1-T315I-mutated and ponatinib-
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resistant CML has not yet been investigated, even though these situations 
currently represent the most challenging clinical scenarios. Here, we 
investigated whether Axl might be a suitable target in CML and determined the 
efficacy of genetic and pharmacologic Axl inhibition in BCR-ABL TKI-sensitive 
and -resistant BCR-ABL1 positive cells, including ABL-T315I-mutated and 
ponatinib-resistant primary cells and animal models.  In light of the tolerability of 
BGB324 in humans this therapeutic approach could be rapidly translated to the 
clinic. 
 
MATERIAL AND METHODS  
 
Animals 
Six to 8 week old female NSG (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) mice were 
purchased from Jackson laboratory (Bar Harbor, ME, USA). All animal 
experiments were carried out in concordance with the institutional guidelines for 
the welfare of animals in experimental neoplasia and were approved by the 
local licensing authority (Behörde für Soziales, Gesundheit, Familie, 
Verbraucherschutz; Amt für Gesundheit und Verbraucherschutz, Hamburg, 
Germany, project number G53/12).  
 
Patient samples 
Axl expression levels were analyzed in bone marrow MNCs from healthy donors 
and from patients with newly diagnosed CML at the University Hospital 
Hamburg-Eppendorf. This analysis was carried out with approval of the local 
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medical ethics committee (approval numbers MC-220/13). In addition, CML 
patients at primary diagnosis were consented in Glasgow for biobanking of their 
stem/progenitor cells and MNCs harvested from PB samples provided during 
the course of their routine clinical care. The research tissue bank had approval 
from the West of Scotland Research Ethics Committee 4 (REC reference 
10/S0704/2). Gas6 levels were determined in the PB plasma of patients with 
chronic phase (CP) and blast crisis (BC). qPCR analysis of Axl mRNA was 
performed using samples of CP CML patients. They were investigated at the 
Jena University Hospital after 6 months of therapy with nilotinib. Furthermore, 
samples from 17 patients with failure or suboptimal response towards BCR-ABL 
TKI treatment according to the current European LeukemiaNet (ELN) 
recommendations were analysed at the same timepoint. Patients were treated 
with imatinib (n=11) or nilotinib (n=6). Four patients showed mutations within the 
BCR-ABL1 kinase domain (G250E, E255K, T315I, F359V, n=1 each). These 
analyses were approved by the local ethics committee. All studies with human 
samples were carried out in accordance with the declaration of Helsinki. 
 
Isolation and culture of MNC and CD34+ cells 
MNCs were isolated from blood or bone marrow using Ficoll-Paque. Primitive 
(CD34+) cells were enriched by positive selection using CliniMACS technology 
and stored frozen in the vapor phase of liquid nitrogen until required.  
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Drug treatment conditions 
Treatments were carried out in serum-free medium containing cytokines with 
different concentrations of BGB324. Imatinib was used at different 
concentrations alone or in combination with BGB324 for 3 or 48 h as indicated 
in the figure legends. In the combinatory experiment the IC50 dose level of 1.5 
µM BGB324 and 500 nM imatinib, respectively were used. Primary MNCs or 
CD34+ isolated from healthy donors or CML cells were treated as specified. 
After 48 h, cell viability was assessed by WST-1 assay (Roche Applied Science, 
Mannheim, Germany). Primary cells from a BCR-ABL TKI-resistant patient and 
a patient with a BCR-ABL1-T315I mutation were treated for 72 h with 100 nM 
ponatinib, 150 nM dasatinib and 3 µM of BGB324 prior to apoptosis and colony 
assays.  
 
Flow cytometry  
Proliferation and apoptosis levels were measured by flow cytometry using BrdU 
incorporation and 7-AAD staining (to exclude dead cells) (BD, Heidelberg, 
Germany), and AnnexinV-FITC/propidium iodide, respectively. Events were 
captured using BD FACS Calibur.  
 
Colony forming assay  
Clonogenic potential of cells surviving in vitro drug treatments was determined 
by colony forming cell assay whereby cells were aliquoted in duplicate in semi-
solid culture medium (Methylcellulose H4034; Stem Cell Technologies), cultured 
for 12 days and colonies scored by light microscopy.  
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Cloning of LeGO vectors and production of lentiviral particles  
Cloning was performed using a LeGO vector for silencing human Axl (for 
detailed protocols and vector maps refer to http://www.lentigo-vectors.de). For 
silencing Axl pLKO.1 vector containing shRNA Axl sequence 5’-
ccggcgaaatcctctatgtcaacatctcgagatgttgacatagaggatttcgttttt-3’ was purchased 
from Sigma MISSION. Only cells with a minimum of 70% knockdown compared 
to controls were used for experiments.  
 
ELISA and qPCR 
Human or murine Gas6 levels were determined in cell culture supernatants and 
peripheral blood plasma using ELISA kits according to the manufacturer’s 
instructions (R&D Systems, Wiesbaden, Germany).  
Quantitative RT-PCR of human Axl was performed with cDNA from PB MNCs 
BCR-ABL TKI-resistant or -sensitive CML patients using premade 
GeneExpression Assays from Applied Biosystems (human primers for Axl 
Hs01064444_m1 and GAPDH Hs99999905_m1) and the Eppendorf 
MasterCycler technology (Eppendorf, Hamburg, Germany).  
 
Western blot analysis 
Western blotting was carried out as described (32). The pAkt, Akt, p-p44/42 
MAPK (pErk1/2), p44/42 MAPK (Erk1/2), pBCR-ABL, BCR-ABL, pCrkl, Crkl, 
pStat5 and Stat5 antibodies were purchased from Cell Signaling (distributed 
through New England Biolabs GmbH, Frankfurt am Main, Germany). β-Actin 
antibody was purchased from Santa Cruz Biotechnology (Heidelberg, 
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Germany). pAxl antibody (Y799) was from R&D Systems (Minneapolis, MN, 
USA). The Axl antibody was a gift from Björn Dahlbäck (Lund, Sweden).  
 
CML mouse models and treatments  
For the BaF3/p210, BaF3/T315I, KCL-22 T315I and KCL-22 PonR xenograft 
model, 1x107 cells were injected subcutaneously into the flank of 6 to 8 week 
NSG mice. Mice were randomized and treated twice daily with placebo, 25 or 
50 mg/kg BGB324 by oral gavage (BID). Mice were sacrificed due to ethical 
regulations. For the systemic model, mouse 6 week old female NSG mice were 
sublethally irradiated and intravenously transplanted the next day with KCL-22 
PonR cells. Three days later, mice were treated with placebo or 25 mg/kg 
BGB324 as described previously. Animals were considered end-stage and 
sacrificed according to ethical regulations when they showed symptoms of hind 
limb paralysis or developed multiple chloromas.  
 
Immunohistochemistry of phospho histone 3 
Tumors were resected and fixed. Image analysis was performed using 
AxioVision imaging software (Carl Zeiss Microscopy). pHH3 positive cells were 
calculated as the number of counted pHH3+ cells per square millimeter of 
analysed tumor tissue.  
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Statistical Analysis    
Data represent mean ± SEM of representative experiments, unless otherwise 
stated. Statistical significance was calculated by student’s t-test unless 
otherwise stated. To study dependence of numerical dependent parameters of 
n>2 categorial variables, ANOVA was used where indicated. Survival analysis 
was carried out using the Kaplan Meier method (log-rank test). All statistical 
analyses have been performed with GraphPad Prism 5.0 (GraphPad Software, 
La Jolla, CA, USA) software.  
 
Supplementary information 
Detailed protocols are provided as Supplementary Information. 
 
RESULTS 
 
Axl signaling is activated in CML cell lines and patient samples  
We previously discovered the role of the Gas6-Axl axis in AML, 
promoting proliferation of leukemia cells and establishing a chemoprotective 
niche, which can be abrogated by Axl-targeting approaches (27). Based on 
these data, we investigated whether Axl might play a role in CML pathobiology. 
To address this question Axl protein expression was evaluated in bone marrow 
mononuclear cells (BMMNCs) from healthy donors and newly diagnosed 
chronic phase (CP) CML patient samples. Immunoblotting revealed presence of 
Axl in all the CML patient samples analyzed, and showed that Axl expression 
levels were enhanced in BMMNCs from seven out of eight CML patients CML 
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patients compared to healthy BMMNCs. In addition, Axl phosphorylation was 
evaluated indicating active signaling of the receptor in seven out of eight CML 
patients (Fig. 1A).  
Axl Western blotting in different CML cell lines showed that the receptor 
was expressed in all human BCR-ABL1+ KCL-22, K562, BV-173 and murine 
BaF3/p210 cell lines, similar to our observations in CML patients. Interestingly, 
Axl phosphorylation was increased in serum-deprived growth conditions 
indicating its increased activity in challenging conditions (Fig. 1B).  
Next, we quantified the levels of secreted Gas6, the main ligand of Axl, in 
serum samples from healthy donors and CML patients in CP and blast crisis 
(BC). Gas6 protein levels were measured by ELISA. The results showed that 
Gas6 serum levels were 2.7-fold and 8.5-fold increased in CP and BC, 
respectively, compared to healthy donors (healthy 1290±684 pg/mL; CP 
3465±405 pg/mL; BC 10940±3868 pg/mL) (Fig. 1C). Hence, increased amounts 
of Gas6 are present in the circulation of CML patients compared to healthy 
subjects.  
Similarly, secreted Gas6 levels were quantified in the different CML cell 
lines in which Axl expression was previously detected, revealing that Gas6 is 
expressed at different levels in these cell lines (Fig. 1D). 
Thus, Axl signaling is activated in MNCs from CML patients and cell 
lines. Furthermore, Gas6 serum levels are increased in CML. Therefore, the 
Gas6-Axl axis might represent a potential therapeutic target in CML and we 
tested whether its genetic or pharmacological inhibition would impair CML cell 
survival. 
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Genetic knock down of Axl inhibits CML cell growth 
In order to investigate if Axl represents a therapeutic target in CML we 
knocked down its expression by means of shRNA in KCL-22 and K562 cells 
(Supplementary Fig. S1A). Silencing of Axl in CML cells decreased their viability 
compared to control transduced cells (Fig. 2A). Knock down of Axl inhibited 
phosphorylation of pStat5, pAkt and pErk, important signaling intermediates for 
CML survival and proliferation (Fig. 2B and Supplementary Fig. S1A).  
 
BGB324 decreases viability of CML cell lines and primary CML cells 
In order to investigate the therapeutic potential of pharmacologic Axl 
inhibition we used the selective clinical-stage small molecule Axl kinase inhibitor 
BGB324 (28, 33). KCL-22 and K562 cells were incubated with different doses of 
BGB324 for 3 hours. Western blot analysis indicated that Axl phosphorylation 
was inhibited in a dose-dependent manner in both cell lines. Thus, BGB324 
blocks its target in CML cells. Beyond that, we were interested in elucidating 
whether treatment with BGB324 affects similar pathways compared to the 
genetic knock down of Axl.  Immunoblot analyses suggested in concordance 
with the genetic blockade phospho(p)Stat5, pAkt and pErk were inhibited upon 
treatment with BGB324 (Fig. 2C).  
Consequently, incubation of KCL-22, K562, BV-173 and murine 
BaF3/p210 cell lines with different concentrations of BGB324 reduced viability 
of these cell lines with an IC50 of 1.8±0.2, 2.4±0.1, 3.0±0.3 and 1.3±0.1 µM, 
respectively (Fig. 2D-G). In addition, MNCs isolated from the bone marrow (BM) 
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of CP CML patients were inhibited with an IC50 of 2.5±0.3 µM (Fig. 2H). In 
contrast, MNCs isolated from BM of healthy donors were almost completely 
resistant to BGB324 (IC50 9.8±1.9 μM, n=6). BGB324 also had activity in vitro 
against primary CP CML CD34+ cells (Fig. 2I). BGB324 inhibited in vitro growth 
of BCR-ABL1+ CD34+ cells with an IC50 of 1100 nM, more than 3-fold lower than 
for CD34+ cells from healthy donors (Fig. 2J and Supplementary Fig. S2A).  
Subsequently, we investigated whether the observed reduction of cell 
viability was due to reduced proliferation and/or increased apoptosis. After 
incubation of CML cell lines with 1.5 μM of BGB324 for 24 h we quantified 
BrdU+ and Annexin V+ cells by means of flow cytometry. These experiments 
indicated that BGB324 treatment inhibited proliferation and inducted apoptosis 
in CML cell lines (Fig. 2K and L and Supplementary Fig. S3A).  
Altogether, these experiments show that Axl inhibition by BGB324 blocks 
proliferation and induces apoptosis of CML cells. 
 
BGB324 does not inhibit BCR-ABL1-induced signaling 
The affinity of BGB324 for Abl was 51.88 nM in biacore assays. The 
selectivity of BGB324 for Axl over Abl was >10-fold and >100-fold in 
biochemical assays and in cellular assays, respectively (33). However, we 
wished to rule out that the observed biological effects might be off-target effects 
of BGB324 via inhibition of BCR-ABL1. In order to address this question KCL-
22 and K562 cells were treated with imatinib or with BGB324. After 3 h BCR-
ABL1 and Crkl phosphorylation were measured by Western blot. As expected, 
phosphorylation of BCR-ABL1 and Crkl was inhibited after imatinib treatment 
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(Supplementary Fig. S4A and B). However, BGB324 did not inhibit BCR-ABL1 
signaling because pBCR-ABL1 and pCrkL levels were unaffected by a broad 
dose range of BGB324 (Fig. 3A and B). 
 
Axl expression is upregulated after BCR-ABL TKI treatment in CML 
Axl overexpression has been implicated in resistance against BCR-ABL 
TKI in imatinib- and nilotinib-insensitive CML cell lines (30, 31). Furthermore, 
upregulation of Axl can confer resistance towards treatment with chemotherapy 
or targeted therapies in different cancers (25, 27). Therefore, in order to 
investigate whether Axl overexpression occurs upon treatment with BCR-ABL 
TKI, KCL-22 and K562 cells were incubated with increasing concentrations of 
imatinib for 48 h and Axl expression was measured. Upon treatment with 
imatinib CML cell lines showed upregulation of Axl at the protein level, in line 
with published data showing upregulation of Axl in BCR-ABL TKI-resistant cell 
lines (Fig. 3C) (31).  
Moreover, Axl expression was evaluated in samples of CP CML patients 
after 6 months of therapy with imatinib or nilotinib. Patient samples were 
grouped depending on whether they were responding according to ELN 
guidelines (34). In concordance with the results observed before, Axl mRNA 
levels were higher in PB MNCs derived from BCR-ABL TKI-resistant patients 
compared to those that were BCR-ABL TKI-sensitive (n=17/20) (Fig. 3D). 
Altogether the data show that upregulation of Axl might be involved in 
resistance towards BCR-ABL TKI in CML. 
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Blockade of Axl exerts additive therapeutic effects with imatinib in CML 
cell lines 
In a next step, we wished to determine the efficacy of simultaneous 
inhibition of Axl and BCR-ABL1 in impairing viability of CML cells. Concomitant 
inhibition of Axl by BGB324 (1.5 μM) and BCR-ABL1 by imatinib (500 nM) both 
used at their IC50 dose level resulted in an additive effect on growth inhibition 
upon combined treatment (Fig. 3E). 
 Moreover, to clarify which signaling pathways are involved in the biological 
effects observed after the combined therapy, key mediators potentially affected 
by both Axl- and BCR-ABL1-induced pathways were investigated. An additive 
effect of inhibition of Stat5 phosphorylation was detected when imatinib and 
BGB324 were combined, indicating that Axl induces phosphorylation of Stat5 by 
BCR-ABL1 independent pathways (Fig. 3F). An additive inhibitory effect on 
phosphorylation of Erk and Akt was not detected (Supplementary Fig. S5A). Of 
note, we could not see an upregulation of Axl in these experiments because 
analysis of phosphorylation of signal transduction intermediates was performed 
after 3 hours, which is too early for detecting differences in protein translation.  
 In order to validate the efficacy of simultaneous inhibition of Axl and BCR-
ABL1, shcontrol- and shAxl-transduced KCL-22 cells were treated with imatinib 
(500 nM) and determined their viability after 48 hours. These experiments 
demonstrated an additive effect of combined BCR-ABL1- and Axl blockade (Fig. 
3G).  
 Altogether, our data indicate that Axl represents a therapeutic target in 
BCR-ABL1-unmutated CML. Inhibition of Axl exerts therapeutic efficacy alone 
and has an additive therapeutic effect when combined with imatinib. We next 
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investigated whether Axl blockade might be of use in BCR-ABL TKI-resistant 
CML. 
 
BGB324 reduces viability of BCR-ABL1 T315I mutated and ponatinib 
resistant CML cell lines  
We investigated different BCR-ABL1+ cell lines harboring the ABL-T315I 
mutation and a novel ponatinib-resistant cell line. The cell line KCL-22 PonR 
was generated by subcloning parental KCL-22 in increasing concentrations of 
ponatinib (35). BCR-ABL1 is unmutated in these cells; however cell death is not 
induced with 100 nM ponatinib, a dose commonly leading to cell death in 
ponatinib-sensitive cells. First, Axl expression was evaluated in base line in 
different BCR-ABL TKI-resistant human KCL-22 and murine BaF3 cell lines. Axl 
phosphorylation was found to be higher in the BCR-ABL TKI-resistant cell lines 
BaF3/T315I, KCL-22 T315I and KCL-22 PonR, when compared to the 
respective parental cell lines (Fig. 4A).  
Thus, Axl could be a therapeutic target in BCR-ABL TKI-resistant CML. 
Next, we treated BaF3/T315I, KCL-22 T315I and KCL-22 PonR cells with 
increasing concentrations of BGB324 and after 48 h cell viability was measured. 
Treatment with BGB324 inhibited cell growth with an IC50 of 0.72±0.1, 3.2±0.3 
and 2.7±0.2 µM in BaF3/T315I, KCL-22 T315I and KCL-22 PonR cells, 
respectively (Fig. 4B-D). When BCR-ABL1 and Crkl phosphorylation were 
measured by Western blot in KCL-22 T315I mutated cells, phosphorylation of 
BCR-ABL1 and Crkl was not modified after treatment with different doses of 
BGB324 or imatinib for 3 h (Supplementary Fig. S6A and B). Thus, also in 
T315I-mutated cells BGB324 does not inhibit BCR-ABL1-induced signaling. 
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Subsequently, proliferation and apoptosis assays were carried out. 
BaF3/T315I, KCL-22 T315I and KCL-22 PonR cells were incubated with 1.5 μM 
of BGB324 for 24 h and BrdU and Annexin V assays were performed. We found 
that BGB324 inhibited proliferation in all the three cell lines studied. In addition, 
BGB324 exerted a pro-apoptotic effect on the BCR-ABL TKI-resistant cell lines 
shown by increased number of Annexin V+ cells upon treatment (Fig. 4E and F 
and Supplementary Fig. S3A). Thus, similar to BCR-ABL1-unmutated cells 
BGB324 reduces proliferation and induces apoptosis in BCR-ABL1-T315I 
mutated and ponatinib-resistant cell lines.  
 
BGB324 induces apoptosis of BCR-ABL1 T315I mutated and BCR-ABL 
TKI-resistant primary CML cells. 
Further, we assessed whether treatment with BGB324 would also have 
biological effects on BCR-ABL1 T315I-mutated and BCR-ABL panTKI-resistant 
primary cells including cells unresponsive to ponatinib. PB MNCs from panBCR-
ABL TKI-resistant (n=1) and BCR-ABL1 T315I-mutated patients (n=2) were 
isolated and treated for 72 h with ponatinib, dasatinib and BGB324 prior to 
colony and apoptosis assays. The colony formation assays indicated that 
BGB324 significantly reduced the colony formation of cells from BCR-ABL TKI-
resistant and BCR-ABL1 T315I-mutated patients compared to control- or BCR-
ABL TKI treatment (Fig. 4G and H). The inhibitory effect of 3 μM BGB324 on 
colony growth is 29.2-fold more pronounced in BCR-ABL TKI-resistant primary 
CML cells compared to CD34+ cells from healthy donors indicating a therapeutic 
window for the drug (Supplementary Fig. S7A). In line with the previous results, 
BGB324 was able to significantly induce apoptosis in cells from all the three 
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studied patients (Fig. 4I-K and Supplementary Fig. S8A). Therefore, BGB324 
blocked growth of colonies and induced apoptosis of BCR-ABL1 T315I-mutated 
and BCR-ABL TKI-resistant (including ponatinib) primary cells. 
Altogether, our data indicate that BGB324 inhibits also CML cells that are 
resistant against current therapy including ponatinib. 
 
BGB324 inhibits T315I-mutated CML in vivo.  
With the evidence that Axl inhibition by BGB324 showed therapeutic 
potential in drug-resistant CML in vitro, we proceeded to investigate its effects in 
vivo. For this purpose two approaches were adopted. In a first step ectopic 
models were used, whereby murine BaF3/p210 and BaF3/T315I cells were 
inoculated subcutaneously into non-obese diabetic (NOD) severe combined 
immunodeficiency gamma (NSG) mice. After 12 days of treatment with BGB324 
significant inhibition of tumor growth was observed in mice bearing p210 BCR-
ABL1+ unmutated tumors (control: 1432±403 mm3; BGB324: 632±229 mm3) 
and in mice bearing BCR-ABL1 T315I-mutant tumors (control: 1751±606 mm3, 
BGB324: 614±224 mm3) (Fig. 5A and B). Therefore, BGB324 exerted a 
reduction in tumor growth of BCR-ABL1+ and T315I-mutated cells in vivo.  
To further elucidate the effects of Axl inhibition on CML tumor cells in 
vivo we analysed the proliferation ratio in tissue from BaF3/p210 and 
BaF3/T315I tumors treated with BGB324 compared to control treatment. Cell 
proliferation as determined by histomorphometric analysis of phospho-histone 
H3 (pHH3) revealed reduced proliferation of CML cells in BGB324-treated 
tumors compared to controls in both cell lines (Fig. 5C-F). Hence, BGB324 
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inhibits proliferation of BCR-ABL1-unmutated and T315I-mutated CML in vivo 
corroborating our in vitro data. 
In order to investigate if BGB324 affected the kinase activity of its direct 
target, the phosphorylation status of Axl was determined in control-treated CML 
tissue compared to BGB324-treated CML tumor tissue. This analysis 
demonstrated inhibition of Axl-phosphorylation by BGB324 treatment, indicating 
target inhibition by the compound. Importantly, Axl inhibition reduced also the 
level of phosphorylated Erk (Fig. 5G). Thus, diminished Erk phosphorylation by 
BGB324 could explain the observed reduced proliferation of CML cells in vivo.  
 
Axl blockade exerts therapeutic effects in human BCR-ABL TKI-
resistant CML in vivo.  
In a next step, we determined whether treatment with BGB324 could also 
reduce tumor growth of BCR-ABL TKI-resistant human CML cells. Therefore, 
T315I-mutated and KCL-22 PonR cells were injected subcutaneously into NSG 
mice and treated by BGB324 or control. These experiments showed a 
significant tumor growth inhibition upon treatment with BGB324 compared to 
control treatment in both models, leading to 65% and 58% regression of tumor 
volume of KCL-22 T315I and KCL-22 PonR tumors, respectively (Fig. 6A and 
B).  
Subsequently, to determine whether reduced proliferation might be 
responsible for decreased growth of BCR-ABL1 T315I-mutated and PonR 
tumors upon treatment with BGB324, cell proliferation was quantified by pHH3 
analysis. The results indicated reduced proliferation of BGB324-treated KCL-22 
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T315I and KCL-22 PonR tumor cells compared to controls (Fig. 6C-F). 
Furthermore, in concordance with the previous results and with our in vitro data, 
Axl phosphorylation was decreased in BGB324-treated tumors. In addition, we 
found that pErk was significantly reduced in lysates from tumor tissues after 
treatment with BGB324 (Fig. 6G).  
 
BGB324 prolongs survival in a Ponatinib-resistant systemic mouse model  
In addition to the ectopic models we also investigated the therapeutic 
effect of BGB324 in a systemic model. For the second in vivo approach, the 
human KCL-22 PonR cells were intravenously injected into sub-lethally 
irradiated NSG mice (36). Three days later, mice were divided in two groups 
and treated with placebo or 25 mg/kg BGB324 as described previously. In this 
aggressive model, treatment with BGB324 resulted in significant prolongation of 
overall survival by 7 days (Fig. 6H).  
Altogether, BGB324 inhibits ABL TKI-resistant and –sensitive CML in 
vitro and in vivo independent of BCR-ABL1 mutational status.  
 
DISCUSSION 
 
BCR-ABL TKI have revolutionized CML treatment, but primary and 
acquired resistance as well as their toxicity continue to pose significant clinical 
challenges. Thus, there is the necessity of searching for new targets and 
personalized therapies (16, 37, 38).  
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The most important findings from our study are: (i) Axl signaling is 
activated in BCR-ABL1 unmutated, T315I-mutated and ponatinib-resistant CML 
cell lines; (ii) genetic blockade of Axl or treatment with the selective small-
molecule Axl inhibitor BGB324 inhibits proliferation and induces apoptosis of 
these cell lines; (iii) BGB324 inhibits primary CD34+ CML cells and inhibits 
colony-formation of T315I-mutated and ponatinib-resistant primary CML cells 
and (iv) BGB324 does not inhibit BCR-ABL1 and exerts additive effects with 
imatinib via inhibition of STAT5 signaling. BGB324 inhibits CML growth in 
different mouse models including a systemic-ponatinib resistant model. 
Altogether, our data indicate that the clinical-stage Axl inhibitor BGB324 
might represent a novel treatment option in CML, potentially useful in 
combination with approved BCR-ABL TKI based on the observed additive effect 
which might lead to a more rapid and/or deeper response. The achievement of 
a deeper response would be clinically meaningful because  the time until which 
a response is achieved and its depth has a pronounced prognostic impact in 
CML (39). Furthermore, a major molecular response is currently an inclusion 
criterion in clinical trials of BCR-ABL TKI discontinuation (40).  
In addition, our data indicate that BGB324 is active in BCR-ABL TKI-
resistant CML cells and mouse models, including T315I-mutated and ponatinib-
resistant systemic mouse models and primary cells. Especially in patients 
harbouring the T315I gatekeeper mutation and in ponatinib-resistant CML novel 
treatment options are warranted. Our data show that BGB324 is active in CML 
resistant to all approved treatments which is consistent with the role of Axl in 
promoting drug resistance in different cancers (41). Importantly, we also 
demonstrate that there is a therapeutic window for the drug, because the effect 
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of BGB324 on survival and colony growth is much less pronounced in healthy 
CD34+ stem cells compared to CML cells. These data show that there is a 
therapeutic window for the drug. This conclusion is also supported by our 
experience in the AML trial BGB324 where the treatment has been overall well-
tolerated in 25 patients (28). 
 We also observed an inhibitory effect of BGB324 on BV-173 cells, which 
resemble ALL (acute lymphocytic leukemia) cells (42), suggesting a therapeutic 
benefit of BGB324 in this subgroup of ALL carrying the Ph chromosome. 
Nevertheless, further studies are necessary to elucidate the therapeutic 
potential of BGB324 in BCR-ABL1+ ALL.  
 Upon investigation of important signal transduction pathways 
promoting CML growth and survival, pronounced reduction of phosphorylated 
MAPK, Stat5 and Akt were found after Axl inhibition. Previous data showed that 
selectivity of BGB324 (formerly known as R428) over ABL was <10-fold in 
biochemical assays and >100-fold higher affinity for Axl versus ABL in cellular 
assays (33). Biochemical biacore data indicate that BGB324 has higher affinity 
to mutated BCR-ABL1 including T315I, M351T and E255K mutations (43). 
Therefore, we wished to investigate whether BGB324 might block BCR-ABL1 
signaling in addition to Axl downstream signaling. Our data indicate that 
BGB324 does not inhibit BCR-ABL1-mediated signaling because its 
phosphorylation and phosphorylation of Crkl (one of the main mediators of 
BCR-ABL1 signaling) was not inhibited with BGB324 in BCR-ABL1 unmutated 
and T315I-mutated cells, even at the highest doses used. Thus, the biological 
effect of BGB324 is due to Axl and not BCR-ABL1 inhibition. It is well-
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established in literature that biochemical selectivity does not always reflect the 
activity of an inhibitor in a living cell (44, 45).  
Recently, an allosteric inhibitor of BCR-ABL1 (ABL001) was discovered, 
which in contrast to the approved BCR-ABL TKI does not bind to the ATP site of 
the kinase domain but induces negative regulation of the kinase activity by an 
allosteric mechanism (46). Thereby, emergence of resistance due to mutations 
in the ATP site can be circumvented in preclinical models. ABL001 is currently 
being investigated in a Phase 1 study. The mechanism of action of ABL001 is 
distinct from BGB324, thus it might be interesting to combine both drugs. 
However, further studies are necessary to investigate this combinatory 
approach. 
 Interestingly, higher levels of Axl expression were found after imatinib 
treatment in CML cell lines and in patients that were BCR-ABL TKI-resistant 
compared to sensitive patients. Overexpression, but not mutation, of Axl 
contributes to drug resistance in other cancers including gastrointestinal stromal 
tumor (GIST) (25), non-small cell lung carcinoma (NSCLC) (26) and in acute 
myeloid leukemia (AML) (27). These data are consistent with our results 
suggesting that upregulation of Axl upon treatment could be involved in 
resistance towards BCR-ABL TKI in CML. Nevertheless, further studies are 
needed to dissect the functional role of Axl in mediating BCR-ABL TKI 
resistance in CML.  
Precedents exist for multi-kinase inhibitor prescribed in CML e.g. 
dasatinib with its predominant activity against both Src and Abl, having the 
advantage of reaching deeper into the stem cell pool (47), but this carries the 
potential disadvantage of inducing dose limiting toxicities, such as pulmonary 
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hypertension (48), and pleural effusion (49), owing to off-target effects. Of the 
clinically available BCR-ABL TKI routinely in use in CML, only bosutinib targets 
Src/Abl and Axl, but at low potency against Axl (174 times higher IC50 for Axl 
versus unmutated BCR-ABL1) (50). Bosutinib is less effective against BCR-
ABL1 mutants, including E255K/V, than against unmutated BCR-ABL1. 
BGB324 with its Axl kinase inhibition profile and activity in unmutated and 
mutated BCR-ABL TKI-resistant and -sensitive cells, including T315I-mutated 
and ponatinib-resistant CML, and its safety in healthy volunteers and AML 
patients (28, 29), may represent a novel treatment option in CML, alone and in 
combination with BCR-ABL TKI. Optimal treatment of CML patients would 
involve a well-tolerated, orally bioavailable, targeted inhibitor that 
simultaneously suppresses BCR-ABL1 unmutated and evolving mutant clones.   
 In summary, our data highlight the advantage to be gained from inhibition 
of Axl even in the most resistant CML cells, and support the need for human 
clinical trials of the novel inhibitor BGB324 at all stages of this disease. 
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FIGURE LEGENDS 
Figure 1. Axl signaling is activated in CML patients and cell lines. A, Western 
blot analysis of Axl expression and phosphorylation (pAxl) showing lower Axl 
and pAxl levels in bone marrow mononuclear cells (MNC) from healthy donors 
compared to newly diagnosed chronic phase (CP) CML patients (n=8/7). 
Densitometric quantification of (pAxl/β-actin)/(Axl/β-actin) from CML was 
normalized to healthy samples. Data are presented as % of healthy donors. B, 
Western blot analysis of pAxl expression in different human BCR-ABL1+ KCL-
22, K562, BV-173 and murine BaF3/p210 cell lines. pAxl expression was 
compared after 24 h of culturing the cells in NM (normal medium, containing 
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10% FCS) or in SF (serum free, containing 0.1% FCS) conditions. 
Densitometric quantification of (pAxl/β-actin)/(total protein expression/β-actin) 
was normalized to NM cultured cells. Data are presented as % of pAxl as 
detected in NM cells (n=3). C, Gas6 ELISA from PB plasma samples indicating 
upregulation of hGas6 in CP and blast crisis (BC) CML compared to healthy 
donors (n=14/50/7). D, Gas6 ELISA determining secreted Gas6 protein levels in 
supernatants from different human BCR-ABL1+ KCL-22, K562, BV-173 and 
murine BaF3/p210 cell lines. Values are presented as the mean of picogram 
per milliliter (pg/ml) from three replicates. *P < 0.05, **P < 0.01 and ***P < 0.001 
(student’s t-test). 
 
Figure 2. BGB324 decreases viability of CML cell lines and primary CML cells. 
A, silencing of Axl expression by shRNA reduced the number of viable KCL-22 
and K562 cells as shown by WST-1 assay. Percentage of viable cells was 
normalized to control-transduced cells (n=3). B, Western blot analyses of 
pStat5, pAkt and pErk after knock-down of Axl expression or (C) after 
incubation with different concentrations of BGB324 (as indicated) for 3 h 
indicating downregulation of these signaling pathways activity in KCL-22 and 
K562 cells (n=3). Densitometric quantification of (phosphorylated protein/β-
actin)/(total protein expression/β-actin) was normalized to control-transduced 
cells and represented as %. D-G, assessment of half maximal inhibitory 
concentration (IC50) for BGB324. Treatments were performed with increasing 
concentrations (0, 1, 2, 3, 4 and 5 µM) of BGB324 (expressed as logarithm) for 
48 h in human KCL-22 (D), K562 (E), BV-173 (F) and murine BaF3/p210 (G) 
cell lines (n=3). H, IC50 of BGB324 in MNCs and (I) in CD34+ cells isolated from 
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bone marrow of CML patients (n=17/6). J, mean of the IC50 of CD34+ cells from 
healthy donors vs. CML patients (n=6/3; P = 0.05). K and L, FACS 
quantification of proliferation (BrdU+ staining) and apoptosis (Annexin V+ 
staining) in different human BCR-ABL1+ KCL-22, K562, BV-173 and murine 
BaF3/p210 cell lines. Proliferation was decreased (K) and apoptosis was 
increased (L) with 1.5 μM of BGB324 after 24 h (n=3). Data are presented as % 
of mean BrdU+ or Annexin V+ cells from three independent experiments. *P < 
0.05, **P < 0.01 and ***P < 0.001 (student’s t-test). 
 
Figure 3. Axl inhibition exerts additive therapeutic effects with BCR-ABL 
inhibitors. A-C, Western blot analysis of BCR-ABL1 (A) and Crkl (B) 
phosphorylation in KCL-22 and K562 cells, showing that is not affected by 
different doses of BGB324 (as indicated) after 3 h of incubation (n=3). 
Densitometric quantification of (phosphorylated protein/β-actin)/(total protein 
expression/β-actin) normalized to control-treated cells and represented as %. C, 
Upregulation of Axl expression in KCL-22 and K562 cells after treatment with 
imatinib (0.75 and 1 μM) for 48 h (n=3). Densitometric quantification of (Axl/β-
actin) normalized to control-treated cells and represented as %. D, Axl mRNA 
levels in CML MNCs measured by qPCR, showing increased Axl expression in 
cells from patients who developed resistance to nilotinib (n=17) after 6 months 
of treatment compared to sensitive patients (n=20). GAPDH was used as a 
housekeeping gene. E, KCL-22 cells were treated with BGB324 (1.5 μM) or 
imatinib (500 nM) as single therapy or in combination for 48 h and cell viability 
was measured by WST-1. BGB324 and imatinib elicited additive antileukemic 
effects in KCL-22 cells (n=3). Percentage of viable cells was normalized to 
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control-treated cells. F, Western blot analysis of phospho-Axl and phospho-
Stat5 levels after BGB324 (1.5 μM) and imatinib (500 nM) treatment for 3 h. 
(n=3). Densitometric quantification of (phosphorylated protein/β-actin)/(total 
protein expression/β-actin) normalized to control-treated cells and represented 
as %. G, WST-1 assay measuring cell viability in sh control- or shAxl-
transduced cells upon imatinib treatment (500 nM) for 48 h. Blocking Axl 
expression increased CML cell sensitivity towards imatinib compared to control-
transduced cells (n=3). *P < 0.05, **P < 0.01 and ***P < 0.001 (student’s t-test). 
 
Figure 4. Blocking Axl inhibits TKI-insensitive BCR-ABL1+ cell lines and primary 
CML cells. A, Western blot analysis of total and phosphorylated Axl expression 
in human KCL-22 T315I, KCL-22 PonR and murine BaF3/T315I BCR-ABL TKI-
resistant cell lines indicating higher pAxl expression levels compared to human 
KCL-22 WT or murine BaF3/p210 cell lines. Densitometric quantification of 
(pAxl/β-actin)/(Axl/β-actin) were normalized to the corresponding control and 
represented as % (n=3). B-D, determination of the IC50 of BGB324. Treatments 
were performed with increased concentrations (0, 1, 2, 3, 4 and 5 µM) of 
BGB324 (expressed as logarithm) for 48 h in the murine BaF3/p210 (B), and in 
the human KCL-22 T315I (C) and KCL-22 PonR (D) cell lines (n=3). E and F, 
FACS quantification of proliferation (BrdU+ staining) and apoptosis (Annexin V+ 
staining) in the murine BaF3/p210, and in the human KCL-22 T315I and KCL-
22 PonR cell lines. Proliferation was decreased (E) and apoptosis increased (F) 
with 1.5 μM of BGB324 after 24 h (n=3). Data are presented as percentage of 
mean BrdU+ or Annexin V+ cells. G-K, colony forming and apoptosis cell assays 
performed using primary cells treated for 72 h with 100 nM ponatinib, 150 nM 
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dasatinib and 3 μM of BGB324. BGB324 induced greater reduction of colony 
growth using cells from a BCR-ABL TKI-resistant patient (including ponatinib) 
without kinase domain mutation (Patient 1, performed in duplicates) (G) and 
from a patient with a BCR-ABL1-T315I mutation (Patient 2, performed in 
duplicates) (H), compared to 100 nM ponatinib. I-K, BGB324 induced apoptosis 
in CML MNCs from Patient 1 (performed in triplicates) (I) and two patients 
harboring a BCR-ABL1-T315I mutation (Patients 2 and 3, performed in 
duplicates) (J and K). *P < 0.05, **P < 0.01 and ***P < 0.001 (student’s t-test).   
 
Figure 5: Axl inhibition reduces growth of BCR-ABL1+ cells in vivo. A and B, 
tumor growth curves in mice injected subcutaneously with BaF3/p210 (A) or 
BaF/T315I (B) cells, revealing reduced tumor volume in animals treated with 
25mg/kg (A and B) and 50mg/kg (B) of BGB324 compared to tumor-bearing 
control mice (n=7, P values are calculated by two-way ANOVA). C and E, 
morphometric analysis of phospho-Histone H3+ (pHH3) cells performed in tumor 
tissue from BaF3/p210 (C) and BaF3/T315I (E) in vivo models indicating 
inhibition of proliferation in tumors treated with 25mg/kg (C and E) and 50mg/kg 
(E) of BGB324 compared to control treated mice (n=7). D and F, representative 
immunohistochemistry pictures of pHH3 staining on sections from BaF3/p210 
(D) or BaF3/T315I (F) control- and BGB324-treated tumors. G, immunoblots for 
Erk and Axl (phosphorylated and total protein) from BaF3/T315I tumor protein 
extracts, demonstrating reduced activation of these signaling pathways after 
treatment with 50mg/kg of BGB324. Densitometric quantification of 
(phosphorylated protein/β-actin)/(total protein expression/β-actin) was 
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normalized to control-treated tumors (n=4/7) and represented as %. *P < 0.05, 
**P < 0.01 and ***P < 0.001. 
 
Figure 6: Axl blockade exerts therapeutic effects in human BCR-ABL TKI-
resistant CML in vivo. A and B, tumor growth curves in mice injected 
subcutaneously with KCL-22 T315I (A) or KCL22 PonR (ponatinib resistant) (B) 
cells, showing reduced tumor volume in animals treated with 25mg/kg of 
BGB324 compared to tumor-bearing control mice (n=8 (A), n=9 (B); P values 
are calculated by two-way ANOVA). C and E, quantification of pHH3+ cells 
performed in tumor tissue from KCL-22 T315I (C) and KCL-22 PonR tumors (E) 
indicating inhibition of proliferation in tumors treated with 25mg/kg of BGB324 
compared to control-treated mice (n=8 (C), n=9 (E)). D and F, representative 
immunohistochemistry pictures of pHH3 staining of sections from KCL-22 T315I 
(D) or KCL-22 PonR (F) control- and BGB324-treated tumors. G, Western blot 
analysis of Erk, Stat5 and Axl (phosphorylated and total protein) from KCL-22 
PonR tumor protein extracts, showing a downregulation of these signaling 
pathways after 25mg/kg of BGB324. Densitometric quantification of 
(phosphorylated protein/β-actin)/(total protein expression/β-actin) was 
normalized to control-treated tumors (n=8/9) and represented as %. H, Kaplan–
Meier curve showing the overall survival (OS) in vivo in the systemic KCL-22 
PonR mouse model revealing a benefit of Axl inhibition with 25mg/kg of 
BGB324 (median OS 36 days (control) versus 43 days (BGB324), n=5). *P < 
0.05, **P < 0.01 and ***P < 0.001. 
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